"TXA costs $10 per treatment, according to the story. Although this cost is characterized as low, the story could have noted that the price may be prohibitively expensive in many poor countries. The story focuses on mortality difference between the TXA and placebo groups and presents the results in absolute terms. It helpfully notes that TXA would need to be adminstered to 66 patients to prevent one death. Although it passes along the claim that TXA might save ""tens of thousands of people"" without questioning it, the story doesn’t hype the assertion quite as vigorously as the competing coverage. The story mentioned there was no increase in deaths due to blood clots in the TXA group. We understand it’s a blog brief – so this is sufficient. The story provides the bare essentials noting the outcomes in absolute numbers and in number needed to treat. Unfortunately, several important facts were not reported including the number of sites involved, the number of countries and other essential attributes of the study. Nonetheless, we’ll give it the benefit of the doubt. No disease-mongering in this story. It’s difficult to find room for an independent perspective in a 245-word brief, and this story didn’t find the room. Numerous other pro-coagulatory agents are used to help control bleeding in trauma patients. The story didn’t mention any of them. The story states that TXA is a 25-year-old medicine that is approved in the U.S. to prevent bleeding in hemophiliacs who have teeth pulled. The story mentions that TXA is already used to control bleeding during surgery and doesn’t portray the treatment as new. While there’s no evidence that this story lifted anything directly from a news release, we can’t be sure to what extent this story may have relied on one. We’ll call it not applicable."
Generic Drug Could Save Many Trauma Patients